What is romosozumab and how is it used in the treatment of osteoporosis?

Romosozumab: A Bone-Building Medication for High-Risk Osteoporosis

Romosozumab is a monoclonal antibody that blocks sclerostin, dramatically increasing bone formation while simultaneously reducing bone resorption, approved specifically for postmenopausal women at very high risk of fracture. 1, 2

Mechanism of Action

Romosozumab works by inhibiting sclerostin binding to osteoblasts, which unleashes a dual effect on bone metabolism 1, 2:

• Increases bone formation through both bone modeling (increasing cross-sectional area) and remodeling (bone repair)
• Decreases bone resorption to a lesser extent
• Produces dramatic increases in bone mineral density (BMD) that exceed other osteoporosis medications

The bone formation marker P1NP peaks at approximately 145% above baseline within 2 weeks, then returns to baseline by month 9. The bone resorption marker CTX decreases by approximately 55% within 2 weeks and remains suppressed throughout the 12-month treatment period 2.

Clinical Efficacy: Fracture Reduction

Romosozumab demonstrates superior fracture reduction compared to both placebo and active comparators 1:

Vertebral Fractures

• 73% reduction vs. placebo at 12 months
• 75% reduction when followed by denosumab at 24 months (compared to placebo followed by denosumab)
• 34% reduction vs. alendronate at 12 months
• 48% reduction when followed by alendronate at 24 months (compared to alendronate alone for 2 years)

Clinical Fractures

• 27-33% reduction at both 12 and 24 months in both major trials

Hip and Nonvertebral Fractures

• 38% hip fracture reduction and 19% nonvertebral fracture reduction at 24 months (significant only in the alendronate-comparison trial with 4,093 patients) 1

BMD Improvements: Unmatched Gains

Romosozumab produces the most dramatic BMD increases of any osteoporosis medication 1:

Compared to placebo at 12 months:

• Lumbar spine: +17.7%
• Total hip: +4.1%

Compared to teriparatide at 12 months:

• Lumbar spine: +9.8% vs. +5.4%
• Femoral neck: +3.2% vs. -0.2%
• Total hip: +2.9% vs. -0.5%

Even in patients previously treated with bisphosphonates for an average of 6.2 years, romosozumab still produced superior BMD gains compared to teriparatide 1.

Administration and Dosing

• Dose: 210 mg subcutaneously monthly (administered as two 105 mg injections) 2
• Duration: Limited to 12 months maximum 3, 2
• Route: Subcutaneous injection
• Supplementation required: 500-1000 mg calcium and 600-800 IU vitamin D daily 1

Who Should Receive Romosozumab

The 2023 American College of Physicians guidelines recommend romosozumab for females with primary osteoporosis at very high risk of fracture (conditional recommendation) 3. The 2020 AACE/ACE guidelines position it as a "rescue drug" for patients at very high fracture risk 1.

Ideal Candidates:

• Postmenopausal women with severe osteoporosis and very high fracture risk
• Patients who have failed or are intolerant to other therapies
• Those previously treated with teriparatide or abaloparatide 1
• Patients with prior radiation exposure 1
• Patients who can tolerate the 12-month treatment course followed by sequential antiresorptive therapy

Currently NOT Approved For:

• Men with osteoporosis (studied but not FDA-approved) 1
• Premenopausal women 2

Critical Safety Considerations

BLACK BOX WARNING: Cardiovascular Risk 1, 2

Do NOT use romosozumab in patients with:

• Recent myocardial infarction (within 1 year)
• Recent stroke (within 1 year)
• High cardiovascular risk

In the alendronate-comparison trial (N=4,093), serious cardiovascular events were significantly more common with romosozumab compared to alendronate, though the increased risk was small and did not persist 1. This finding led to the black box warning.

Hypocalcemia Risk 2

• Contraindicated in patients with hypocalcemia - must correct before initiating treatment
• Severe renal impairment (eGFR 15-29 mL/min/1.73 m²) or dialysis patients are at greater risk
• Monitor calcium levels closely in high-risk patients
• Ensure adequate calcium and vitamin D supplementation

Other Adverse Effects

• Arthralgia and headache are common
• Injection site reactions
• Anti-romosozumab antibody development (can reduce drug concentrations by up to 22%; neutralizing antibodies by up to 63%) 2

Sequential Therapy: Essential for Sustained Benefit

Romosozumab MUST be followed by antiresorptive therapy - this is not optional 1, 3:

Recommended Sequential Approach:

1. Romosozumab for 12 months (maximum duration)
2. Immediately transition to antiresorptive therapy:
   • Denosumab (preferred based on trial data showing 75% vertebral fracture reduction) 1
   • OR bisphosphonate (alendronate showed 48% vertebral fracture reduction when following romosozumab) 1

Critical Points:

• No washout period or drug holiday between romosozumab and antiresorptive therapy 1
• Without sequential therapy, BMD gains will be lost
• The dramatic fracture reduction benefits persist when followed by appropriate antiresorptive treatment 1

Comparison to Other Anabolic Agents

Romosozumab produces greater BMD increases than teriparatide across all skeletal sites, even in patients previously treated with bisphosphonates 1. However, teriparatide may have a more favorable cardiovascular safety profile.

Key Differences:

• Romosozumab: 12-month maximum duration, dual mechanism (anabolic + antiresorptive), cardiovascular concerns
• Teriparatide/Abaloparatide: 24-month maximum duration, purely anabolic, no cardiovascular signal but osteosarcoma warning

Special Populations

Renal Impairment

• No dose adjustment required for mild-to-moderate renal impairment 2
• Severe renal impairment or dialysis: Can be used but requires careful calcium monitoring and supplementation due to increased hypocalcemia risk 2

Prior Bisphosphonate Use

• Romosozumab remains effective even after prolonged bisphosphonate therapy (mean 6.2 years) 1
• BMD gains are still superior to teriparatide in this population

Monitoring

• Baseline: Calcium levels (must be normal), cardiovascular risk assessment, BMD
• During treatment: Calcium levels (especially in renal impairment), clinical assessment
• Post-treatment: BMD at 1-2 years to confirm response to sequential antiresorptive therapy 1

Cost and Access Considerations

Romosozumab is significantly more expensive than bisphosphonates 3. The 2023 ACP guidelines recommend bisphosphonates as first-line treatment, with romosozumab reserved for very high-risk patients, partly due to cost considerations 3.

Clinical Positioning

Romosozumab should be viewed as a "rescue drug" for patients at very high fracture risk 1. It is not a first-line agent for most patients with osteoporosis. Bisphosphonates remain the recommended initial therapy for most postmenopausal women with osteoporosis due to their proven efficacy, safety profile, and low cost 3.

Use romosozumab when the fracture risk is so high that the potential benefits of dramatic BMD increases and superior fracture reduction outweigh the cardiovascular concerns and cost - typically in patients with severe osteoporosis, multiple prior fractures, or those who have failed other therapies.